Bitget COO Vugar Usi Zade Speaks on Future of Web3 at Economic Times World Leaders Forum 28-08-2025, 09:16

Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26

WiDEF announces first awardees of funding to close the gender digital divide 18-11-2024, 21:00